Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Novel Triazolopyridine-Based BRD4 Inhibitors as Potent HIV-1 Latency Reversing Agents.
Wang YK, Huang XS, Sun H, Ma MD, Yu HP, Hu W, Li ZY, Li Z, Luo RH, Tian RR, Xiao TF, Yang LM, Zheng YT, Li X. Wang YK, et al. Among authors: ma md. ACS Med Chem Lett. 2023 Dec 14;15(1):60-68. doi: 10.1021/acsmedchemlett.3c00373. eCollection 2024 Jan 11. ACS Med Chem Lett. 2023. PMID: 38229757 Free PMC article.
Synthesis and anti-HIV activities of phorbol derivatives.
Huang X, Tang C, Huang X, Yang Y, Li Q, Ma M, Zhao L, Yang L, Cui Y, Zhang Z, Zheng Y, Zhang J. Huang X, et al. Chin J Nat Med. 2024 Feb;22(2):146-160. doi: 10.1016/S1875-5364(24)60587-X. Chin J Nat Med. 2024. PMID: 38342567
Seco-cyclic phorbol derivatives and their anti-HIV-1 activities.
Huang X, Huang X, Li Q, Ma M, Cui Y, Yang L, Wang H, Luo R, Chen J, Yang J, Lin J, Li D, Zheng Y, Zhang J. Huang X, et al. Chin J Nat Med. 2024 Apr;22(4):365-374. doi: 10.1016/S1875-5364(24)60630-8. Chin J Nat Med. 2024. PMID: 38658099
De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial.
Chen XC, Jiao DC, Qiao JH, Wang CZ, Sun XF, Lu ZD, Li LF, Zhang CJ, Yan M, Wei Y, Chen B, Feng YQ, Deng M, Ma MD, Plichta JK, He YW, Liu ZZ. Chen XC, et al. Among authors: ma md. Lancet Oncol. 2025 Jan;26(1):27-36. doi: 10.1016/S1470-2045(24)00581-3. Epub 2024 Nov 26. Lancet Oncol. 2025. PMID: 39612919 Clinical Trial.
33 results